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Abstract 
Background/Aims: Sterol regulatory element-binding protein (SREBP) 1, the master regulator 
of lipogenesis, was shown to be associated with non-alcoholic fatty liver disease, which is 
attributed to its major isoform SREBP1c. Based on studies in mice, the minor isoform SREBP1a 
is regarded as negligible for hepatic lipogenesis. This study aims to elucidate the expression 
and functional role of SREBP1a in human liver. Methods: mRNA expression of both isoforms 
was quantified in cohorts of human livers and primary human hepatocytes. Hepatocytes 
were treated with PF-429242 to inhibit the proteolytic activation of SREBP precursor protein. 
SREBP1a-specific and pan-SREBP1 knock-down were performed by transfection of respective 
siRNAs. Lipogenic SREBP-target gene expression was analyzed by real-time RT-PCR. Results: 
In human liver, SREBP1a accounts for up to half of the total SREBP1 pool. Treatment with 
PF-429242 indicated SREBP-dependent auto-regulation of SREBP1a, which however was 
much weaker than of SREBP1c. SREBP1a-specific knock-down also reduced significantly the 
expression of SREBP1c and of SREBP-target genes. Regarding most SREBP-target genes, 
simultaneous knock-down of both isoforms resulted in effects of only similar extent as 
SREBP1a-specific knock-down. Conclusion: We here showed that SREBP1a is significantly 
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The transcription factor sterol regulatory element-binding protein (SREBP) 1 was 
recognized as the master regulator of lipogenesis, especially regulating genes encoding 
key enzymes of fatty acid and triglyceride biosynthesis in the liver [1]. An increase in de 
novo lipogenesis was recently shown to substantially contribute to the excess storage of 
triglycerides in non-alcoholic fatty liver disease (NAFLD) [2], which encompasses a spectrum 
of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). While 
numerous reports showed up-regulation of SREBP1 in human NAFLD [3, and references 
therein], studies with SREBP1-transgenic mice [4, 5] and of SREBP1 knock-out or knock-
down in murine NAFLD disease models [6, 7] further confirmed the crucial role of the gene 
in hepatic steatosis.
In mammals, two isoforms of SREBP1 protein, SREBP1a and SREBP1c, are known, 
which arise by the use of two alternative first exons. Exon 1a encodes the unique 29 amino 
acids of the SREBP1a NH2-terminus, whereas exon 1c only encodes 5 unique amino acids 
[8]. Thus, the NH2-terminal acidic transcriptional activation domain of SREBP1a is 24 
amino acids longer and harbors 12 negatively charged amino acids, whereas the respective 
domain of SREBP1c contains only 6 negatively charged residues [9]. Consequently, SREBP1a 
proved to be the by far stronger transcriptional activator of the two isoforms, both in vitro 
[10] and in vivo [11]. SREBP1 proteins are produced as precursor proteins, which reside 
in the endoplasmic reticulum. Sequential proteolytic digests by site 1 and site 2 proteases 
are required to release the NH2-terminal part of the protein, which then translocates to the 
nucleus and acts as the mature transcription factor [9]. 
SREBP1c, which is the dominant isoform in many mouse tissues, including liver [8], is 
mediating the nutritional control of hepatic lipogenic gene expression [12], as its expression 
[13] and proteolytic activation [14] are induced by insulin signaling. Thus, it is the isoform 
which has been implicated in NAFLD. In contrast the physiological and pathophysiological 
role of SREBP1a in the liver is less well understood. SREBP1a is commonly regarded as being 
negligible in liver, as it was previously shown in mice to be expressed at 10-fold lower levels 
than SREBP1c [8]. In the same study, it was further shown that 1a is 6-fold outnumbered 
by 1c in human liver, which however was based only on the analysis of an individual liver 
sample. Given the well-known interindividual variability of gene expression in humans, 
we re-analyzed here the contribution of SREBP1a to the total hepatic SREBP1 pool and 
determined its role in the control of human hepatic SREBP-target gene expression.
Materials and Methods
Plasmids 
Partial sequences of exons 1a and 2 (pos. 60-423 of NM_004176) and exons 1c and 2 (pos. 341-670 
of NM_001005291) of human SREBP1 were amplified by PCR out of human liver cDNA using appropriate 
primers and cloned into pBluescript KS M13- (Agilent Technologies, Santa Clara, CA), thereby creating 
pbl-SREBP1a-TQ and pbl-SREBP1c-TQ, respectively.  Identity of the cloned inserts was confirmed by 
sequencing. The insert of pbl-SREBP1a-TQ was further subcloned into pbl-SREBP1c-TQ, thereby creating 
pbl-SREBP1a+1c-TQ, which contains both SREBP1a and -1c specific regions.  
Human liver biobank and NAFLD grading 
The human liver biobank, consisting of histologically normal, non-tumorous liver tissue samples, 
collected from patients undergoing liver surgery at the University Medical Center Charité (Berlin, Germany), 
was described previously [15]. The study was approved by the local ethical committees of the Charité, 
Humboldt University, Berlin, and University of Tübingen and conducted in accordance with the Declaration of 
Helsinki. Written informed consent was obtained from each patient. NAFLD livers, identified retrospectively 
by histological analysis, were graded as non-NASH, mild NASH and moderate to severe NASH as described 
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Primary human hepatocytes 
Human hepatocytes were prepared from tissue samples of liver resections, which were obtained from 
patients, who underwent partial hepatectomy because of liver tumors at the University Medical Center 
Charité, Berlin, Germany and at the Hospital Großhadern, Munich, Germany, as described previously [17]. 
Donor data are available on request. The isolated cells were seeded at 1.5 x 106 cells/well into collagen type 
I-coated 6-well plates and treated with 0.1% DMSO for 48 h [17]. Hepatocytes from three different donors 
were also treated with 10 µM PF-429242 (Tocris Bioscience, Bristol, UK). 
siRNA-mediated gene knock-down 
Primary human hepatocytes were seeded at 4 x 105 or 1 x 106 cells/well into collagen type-I-coated 
12-or 6-well plates, respectively. After 6-12 h, cells were transfected with non-targeting negative control 
siRNA (Silencer Select negative control 1), Silencer Select siRNA targeting 5’-CCA TGG ACG AGC CAC CCT 
T-3’ (pos. 193-211 of NM_004176) in exon 1a of SREBP1 or Silencer Select siRNA targeting 5’-CCA CTC 
CAT TGA AGA TGT A-3’ (pos. 505-523 of NM_004176) in exon 2 of SREBP1 (ID# s129), which is common 
to SREBP1a and -1c transcripts. Silencer Select siRNAs were provided or custom-synthesized by Life 
Technologies (Darmstadt, Germany), and transfected at a final concentration of 20 nM using Lipofectamine 
RNAiMAX (Life Technologies). Culture medium (Williams’ E medium, supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1% DMSO, 0.032 I.U./ml insulin 
and 100 nM dexamethasone) was renewed daily and cells were harvested for RNA and protein analysis 72 
h after transfection.
RNA preparation and cDNA synthesis 
Total RNA was prepared using the NucleoSpin RNA kit (Machery-Nagel, Düren, Germany), including 
removal of contaminating genomic DNA by DNase I digest. The integrity of the isolated RNA was confirmed 
by formaldehyde-agarose gel electrophoresis or by Agilent2100 Bioanalyzer analysis (Agilent). First 
strand cDNA was synthesized from 0.32 µg RNA with random hexamer primers and MultiScribe reverse 
transcriptase using TaqMan reverse transcription reagents (Life Technologies) in a volume of 16 µl, 
according to manufacturer’s standard protocol.  
Quantitative real-time RT-PCR 
Absolute quantification analyses were performed by TaqMan Real-time RT-PCR using the 7900 Real-
Time PCR System (Applied Biosystems, Foster City, CA). SREBP1a and -1c assays were set up with cDNA 
samples, pre-amplified for 10 cycles to shift sample CT values into mid of standard curve range, and qPCR 
MasterMix (Eurogentec, Liege, Belgium). Pre-amplification was performed as described previously [16]. 
Assays were done in triplicate. The commercial TaqMan gene expression assay Hs00231674_m1 (Applied 
Biosystems), consisting of a pre-designed primer/probe set, with the probe targeting the exon 1a/2 
junction (5’-GAC CGA CAT CGA AG│A CAT GCT TCA G-3’), was used to quantify SREBP1a. Oligonucleotides 
used for SREBP1c were as follows: 900 nM each of primers 5’- CGG AGC CAT GGA TTG CA-3’ (exon 1c) and 
5’- GGA AGT CAC TGT CTT GGT TGT TGA-3’ (exon 2); 250 nM of 6-carboxyfluorescein labeled probe 5’- CTT 
TCG AAG │ACA TGC TTC A-3’ (exon 1c/2). The specificity of the assays was determined using linearized 
pbl-SREBP1a-TQ and pbl-SREBP1c-TQ plasmids. Both assays demonstrated > 3 x 104–fold higher selectivity 
for the matching cDNA. Serial 10x dilutions of linearized plasmid pbl-SREBP1a+1c-TQ, were used to create 
the standard curves for both assays, ranging from 1.2 x 102 to 1.2 x 107 copies. Amplification efficiencies of 
SREBP1a and SREBP1c assays were 99% and 97%, respectively. These were determined using the slopes 
of the respective SREBP1a and SREBP1c standard curves, which were -3.346 and -3.403, with R2 values of 
0.9992 and 0.9999, respectively. Absolute gene expression levels of SREBP1a and SREBP1c were calculated 
by the SDS 2.3 analysis software of the 7900 Real Time PCR System, using the linear equations of the 
respective standard curves. Gene expression levels were normalized to corresponding 18S rRNA levels, as 
determined using the 18S rRNA assay previously described [17].
Relative quantification analyses were performed by TaqMan Real-time RT-PCR using the BioMark HD 
system and FLEXsix Gene Expression Integrated Fluidic Circuits (Fluidigm, South San Francisco, CA), as 
described previously [16]. Commercial TaqMan gene expression assays (Life Technologies), consisting of pre-
designed primer/probe sets, were used as follows: Hs01046047_m1 (ACACA), Hs00153715_m1 (ACACB), 
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Hs01650979_m1 (INSIG1), Hs99999902_m1 (RPLP0), (Hs01682761_m1 (SCD) and Hs00930058_m1 
(THRSP). Assays were performed in triplicates. Gene expression levels were normalized to corresponding 
18S rRNA levels. 
Protein analysis
Hepatocytes were lysed with a buffer according to Sundqvist et al. [18], which was composed 
of 50 mM HEPES pH 7.2, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 2 mM sodium orthovanadate, 10 mM 
β-glycerophosphate, 1% (v/v) Triton-X-100, 10% (v/v) glycerol, 10 mM sodium butyrate, 0.1% (w/v) SDS, 
0.5% (w/v) sodium deoxycholate, 1 mM PMSF, 1x HALT protease inhibitor cocktail (Pierce), by incubation 
on ice for 10 min and sonication in the Bioruptor ultrasonic water bath (Diagenode, Liege, Belgium). To avoid 
proteasomal degradation of mature SREBP1, cells were treated with 25 µM MG132 (Santa Cruz, Dallas, TX, 
USA) 2 h before harvesting. Total protein lysates were quantified using the bicinchoninic acid method and 
further used for standard protein gel electrophoresis and Western blotting. Nitrocellulose membranes were 
incubated with the mouse monoclonal SREBP1-specific antibody 2A4 (Santa Cruz). Fluorescence intensity 
of bound IRDye® 800CW-labeled goat anti-mouse secondary antibody (LI-COR, Lincoln, NE, USA) was 
analyzed and quantified using the Odyssey Infrared Imaging System (LI-COR). Equal protein loading was 
verified by comparing to β-actin levels, which were determined using mouse monoclonal antibody AC-15 
(Sigma-Aldrich, Taufkirchen, Germany) and IRDye® 680RD-labeled goat anti-mouse secondary antibody 
(LI-COR). 
Quantification of de novo lipogenesis 
Incorporation of 14C-labeled acetic acid into lipids was used as a measure of de novo lipogenesis as 
described previously [16].
Data analysis 
Data are presented as mean ± SD of at least three replicate measurements, if not indicated otherwise. 
Analysis of the statistical significance of differences between medians or means was performed with 
statistical tests as indicated, using GraphPad Prism version 6.05 (GraphPad Software, La Jolla, CA).
Results
Expression of SREBP1 transcripts in human liver and NAFLD disease progression
Absolute quantification of the expression of the two alternative transcripts of SREBP1, 
-1a and -1c, was established to allow for the calculation of their respective contribution to the 
total hepatic SREBP1 pool. SREBP1a showed lower median expression than SREBP1c, both 
in human liver (Fig. 1A) and primary human hepatocytes (Fig. 1B). Interindividual variability 
of SREBP1a expression demonstrated to be smaller in liver (6-fold) and in hepatocytes 
(3-fold), than of SREBP1c expression (17- and 7-fold, respectively). Neither SREBP1a nor 
SREBP1c expression was influenced by sex or age. The median expression of both transcripts 
increased during NASH progression, thereby confirming our previous results [16], which 
were obtained by relative quantification analysis and did thus not allow comparison of 
expression levels of the two alternative transcripts. SREBP1a median transcript levels 
demonstrated to be lower than SREBP1c levels in each NAFLD subgroup (Fig. 1C). Based on 
the absolute expression data, the ratio of both transcripts was calculated. Figure 2A shows 
that median ratio of SREBP1a:SREBP1c was 0.35 (range 0.17 to 1.1) in liver and 0.59 (range 
0.25 to 1.4) in primary hepatocytes. Thus, SREBP1a contributed 15-52% (median 26%) to 
the total SREBP1 pool in this liver cohort and 20-58% (median 37%) in hepatocytes. The 
ratio of both transcripts was not altered significantly in NAFLD progression, suggesting that 
the disease did not differentially affect their expression (Fig. 2B). In summary, these data 
clearly show that SREBP1a contributes considerably to human hepatic SREBP1 expression. 
SREBP-dependent auto-regulation of human hepatic SREBP1 transcripts
Expression of the two SREBP1 transcripts showed to be highly correlated in human 
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the other. The latter possibility is supported by the previously shown auto-regulation of 
mouse SREBP1c promoter activity by SREBP1 protein [19]. Similar auto-regulation of the 1a 
promoter has not been described to the best of our knowledge. To analyze a possible auto-
regulation of human SREBP1 transcripts by SREBP protein, primary human hepatocytes 
were treated with PF-429242, a specific inhibitor of site 1 protease [20], which participates 
in formation of the mature, transcriptionally active SREBP proteins by site-specific cleavage 
of the SREBP precursor proteins [21]. Figure 4A shows that treatment with PF-429242 
blocked the formation of the mature SREBP1 proteins. By comparing SREBP1 protein 
expression in hepatocytes with or without significant expression of the 1c transcript 
Fig. 1. SREBP1 transcript expression in 
human liver and primary hepatocytes. Ab-
solute SREBP1a and -1c mRNA expression 
data, as copies per 106 copies 18S rRNA, in 
65 human livers (A) and primary human 
hepatocytes of 22 donors (B) are presen-
ted as box and whisker plots, with boxes 
representing the 25th–75th percentiles, 
medians indicated by horizontal lines and 
whiskers showing minimum and maxi-
mum values. Data were analyzed by Wil-
coxon matched-pairs signed rank test. (C) 
Absolute quantification of SREBP1a and 
-1c mRNA expression in NAFLD-categori-
zed human liver samples is shown as de-
scribed above. Wilcoxon matched-pairs si-
gned rank test was used for the analysis of 
differences between 1a and 1c expression, 
whereas Kruskal-Wallis test with Dunn’s 
multiple comparisons test was used for 
the analysis of differences to the non-
NASH group, which was performed sepa-
rately for SREBP1a and -1c. Asterisks show 
statistical significant differences as indica-
ted. Daggers indicate statistical significant 
Fig. 2. Hepatic SREB-
P1a:SREBP1c expression 
ratios. (A) Scatter blots 
of the individual ratios 
of SREBP1a:SREBP1c ex-
pression in livers and pri-
mary human hepatocytes 
(PHH) with lines indica-
ting medians. Data were 
analyzed by Mann-Whit-
ney test. ***, p<0.001. (B) 
Scatter plots of the indi-
vidual ratios of hepatic 
differences to the respective expression in the non-NASH group. †, p<0.05; ††, p<0.01; ***,†††, p<0.001.
SREBP1a:SREBP1c expression in NAFLD progression with lines indicating medians. Absence of statistical 
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Fig. 3. Expression of SREBP1 transcripts correlates in liver and primary human hepatocytes. Correlation 
analysis of SREBP1a and -1c expression in human livers (A) and primary human hepatocytes (B), using the 
log2-transformed mRNA expression data shown in Fig. 1A,B. 
Fig. 4. Blocking the proteolytic ac-
tivation of SREBP1 protein results 
in decrease of lipogenic gene ex-
pression and de novo lipogenesis. 
(A) Representative Western blot of 
SREBP1 protein expression in pri-
mary human hepatocytes (donor 
RH19), which have been treated 
for 48 h with 0.1% solvent DMSO 
(-PF) or 10 µM PF-429242 (+PF). 
p-SREBP1 and m-SREBP1 indicate 
precursor and mature SREBP1 pro-
teins, respectively. (B) Top, Western 
blot analysis of SREBP1 protein in 
hepatocytes of donors RH19 and 
TH04. Protein lysates of cells, trans-
fected with control siRNA (see Fig. 
5), were used. The image of the 
RH19 lane is a copy of the respecti-
ve lane of Fig. 5D, left panel. Bottom, 
absolute quantification of SREBP1a 
and -1c mRNA expression in corre-
spondingly treated hepatocytes of 
the same donors. (C) Relative SREB-
P1a and -1c mRNA expression in 
primary human hepatocytes (n=3, 
donors GH23, GH26, RH19), trea-
ted as described in (A). Statistical 
significant differences to respective 
expression levels in cells treated 
with DMSO only, which were designated as 1, were analyzed by one sample t-test. (D) De novo lipogenesis 
was determined in hepatocytes of donor GH-23, which were treated as described in (A). The mean value of 
cells (n=3) treated with solvent only, was designated as 1. Data were analyzed by unpaired t-test. (E) The 
relative mRNA expression of the indicated lipogenic SREBP-target genes was determined in hepatocytes 
(n=3, donors GH23, GH26, RH19). RNA samples as in (C). The respective expression levels in cells, treated 
with solvent only, were designated as 1. Data were analyzed as described in (C). Asterisks indicate statistical 
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variant, the bands corresponding to mature SREBP1a and -1c isoforms were unequivocally 
identified (Fig. 4B). Loss of 1c transcript expression was observed in hepatocytes of a single 
donor, which were accidentally cultured at low cell density, a culture condition promoting 
dedifferentiation. In accordance with the previously described auto-regulation of SREBP1c 
promoter activity, treatment with PF-429242 resulted in 99% decrease of SREBP1c mRNA 
expression. In contrast, SREBP1a mRNA was only reduced by 67 ± 13% (Fig. 4C). The strong 
down-regulation of total SREBP1 mRNA by PF-429242 most likely explains the decrease 
observed also in the expression of SREBP1 precursor protein (Fig. 4A). In agreement with 
the well-known role of SREBP1 in fatty acid synthesis, PF-429242 further resulted in 60% 
reduction of hepatic de novo lipogenesis (Fig. 4D), which was reflected in the consistent 
down-regulation of lipogenic SREBP-target gene expression (Fig. 4E). The negative control 
gene RPLP0 was not affected by treatment with PF-429242. These data confirm that mRNA 
expression of human SREBP1c is strongly auto-regulated by SREBP protein, whereas SREBP-
dependent regulation of 1a mRNA appears to be variable and less prominent. 
Fig. 5. SREBP1 mRNA 
and protein knock-
down by SREBP1a-spe-
cific and pan-SREBP1 
siRNAs. (A) Absolute 
quantification of SREB-
P1a and -1c mRNA ex-
pression in primary hu-
man hepatocytes from 
donors RH19, RH20 and 
GH26, transfected for 
72 h with control siRNA 
(siCtr), siRNA specific 
for SREBP1 exon 1a 
(si1a) or siRNA specific 
for the SREBP1 com-
mon exon 2 (si1pan). 
(B) Mean fold changes 
± SD (n=3) of SREBP1 
mRNA expression, cal-
culated from the ex-
pression data shown 
in (A). Respective ex-
pression levels of con-
trol siRNA-transfected 
cells were designated 
as 1. Statistical signifi-
cant differences to this 
value were analyzed by 
one sample t-test. (C) 
Relative quantification 
of mature SREBP1 pro-
teins in hepatocytes, transfected with siRNAs as described in (A). Quantification was performed by densito-
metric analysis of the respective specific bands of the Western blots shown in (D). Data are shown as mean 
fold changes ± SD (n=3). Respective expression levels in control siRNA-transfected cells were designated as 
1. Data analysis was performed as described in (B). (D) Western blots of SREBP1 protein expression in he-
patocytes of donors RH19, RH20 and GH26, transfected as described in (A). SREBP1 precursor (p-1), mature 
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SREBP1a participates in human hepatic lipogenic gene expression
As we showed above that expression of the major transcript SREBP1c is largely 
dependent on auto-regulation by SREBP protein, we hypothesized that the 1a isoform, 
which is known to be the by far stronger transcriptional activator, may contribute to the 
transcriptional control of hepatic SREBP1c and SREBP target genes. Pan-SREBP1- and 1a 
transcript-specific knock-down were performed in primary human hepatocytes by transient 
transfection of siRNA specific for the common exon 2 or exon 1a of SREBP1, respectively. 
Figure 5A shows that SREBP1 mRNA knock-down efficiencies were highly comparable 
between the individual hepatocyte cultures. The partial reduction of SREBP1c transcript 
expression by SREBP1a-specific knock-down is most likely explained by decrease in SREBP-
dependent auto-regulation of the 1c transcript, due to the knock-down of SREBP1a. Ratios of 
SREBP1a:SREBP1c transcripts of the individual hepatocyte cultures, transfected with control 
siRNA, were all in the same range (mean 0.45 ± 0.11). SREBP1a-specific siRNA resulted on 
average in 80% knock-down of the corresponding transcript, whereas pan-SREBP1 siRNA 
decreased the expression of both SRERBP1a and -1c transcripts by ≥ 80% (Fig. 5B). Due 
Fig. 6. SREBP1a contribu-
tes to hepatic SREBP-target 
gene expression. (A) Relative 
quantification of lipogenic 
SREBP target gene expressi-
on in hepatocytes from indi-
vidual donors RH19, RH20 
and GH26, transfected with 
siRNA as described in the 
legend of Fig. 5. Respective 
mRNA expression levels of 
hepatocytes transfected with 
control siRNA (means of tri-
plicate measurements) were 
designated as 1. (B) Mean 
fold changes ± S.D. (n=3 do-
nors) of gene expression by 
SREBP1 knock-down. Stati-
stical significant differences 
to the expression levels in 
control siRNA-transfected 
cells, designated as 1, were 
determined by one sample 
t-test and indicated by aste-
risks. Daggers denote stati-
stical significant differences 
between fold changes of gene 
expression by SREBP1a-spe-
cific (si1a) and pan-SREBP1 
(si1pan) siRNAs, as calcu-
lated by two-way repeated 
measures ANOVA with Si-
dak’s multiple comparisons 
test for the genes showing a 
significant knock-down by at 
least one siRNA. *,†, p<0.05; 
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to the limited and variable effect of SREBP1a-specific siRNA on the expression of the 1c 
transcript (mean reduction of 30%), this siRNA resulted on average only in 46% reduction 
of total SREBP1 mRNA expression. Protein expression levels of the mature SREBP1a and 
-1c isoforms, as well as of total mature SREBP1, were correspondingly reduced (Fig. 5C,D). 
Regarding the SREBP1 precursor proteins, where it was not possible to discriminate between 
the isoforms, SREBP1a-specific knock-down resulted on average in 60% reduction, whereas 
pan-SREBP1 knock-down reduced the expression on average by 84% (Fig. 5D). Thus effects 
on the SREBP1 precursor proteins were identical with the effects on total mature SREBP1 
proteins.
Irrespective of the fact that the efficacies of SREBP1a-specific and pan-SREBP1 knock-
down were highly comparable between the individual hepatocyte cultures, the effect on 
SREBP-dependent lipogenic gene expression differed between them (Fig. 6A). Statistical 
analysis using the mean values of the three donors showed that the expression of most 
lipogenic SREBP-target genes decreased significantly by transfection of SREBP1a-specific 
and/or pan-SREBP1 siRNA (Fig. 6B). However, the extent of the effect was also variable 
between the genes. While ACSS2, ACACA, ACACB, FASN and SCD were down-regulated by 
20-40%, THRSP and INSIG1 showed 60-80% reduction by at least one siRNA. For most 
genes, knock-down of both SREBP1a and -1c, by transfection of pan-SREBP1 siRNA, resulted 
in effects of only similar extent as observed with SREBP1a-specific knock-down. Solely 
THRSP and INSIG1 exhibited a stronger down-regulation by pan-SREBP1 knock-down than 
by SREBP1a-specific knock-down (Fig. 6B). The expression of ACLY and ELOVL6 was not 
significantly altered by any of the two SREBP1-specific siRNAs. In summary, these data 
clearly indicate that SREBP1a significantly contributes to the transcriptional control of 
human hepatic lipogenic SREBP-target gene expression.
Discussion
Given the results here presented, SREBP1a no longer may be regarded as negligible 
for the control of human hepatic lipogenesis, as it contributes to up to half of the total 
hepatic SREBP1 pool in individual livers and participates in hepatic lipogenic SREBP1-target 
gene expression. The interindividual variability of hepatic SREBP1a mRNA expression 
was much smaller than that of 1c, both in human liver and primary human hepatocytes. 
In mice, SREBP1c is strongly regulated by insulin signaling [13]. Even if insulin data from 
the patients, of whom liver tissue samples were obtained, have not been recorded, it may 
be speculated that interindividual variability of insulin levels contributes to the variable 
expression of 1c in human livers. The variability of 1c expression in primary human 
hepatocytes, which was lower than in liver, has to be explained differently, as they were all 
cultivated in the same insulin-containing cell culture medium. It is well known that primary 
hepatocytes dedifferentiate in cell culture to a variable extent, a process which is already 
initiated during isolation [22]. Variable extent of dedifferentiation may thus contribute to 
the variability of SREBP1c transcript expression in cultured primary human hepatocytes. 
On the other hand, cultivation-dependent dedifferentiation may explain the significantly 
higher ratio of SREBP1a:SREBP1c in primary hepatocytes. In contrast to 1c, 1a was shown 
to be at best modestly affected by insulin in mice [13]. Nevertheless, expression of both 
transcripts proved to be highly correlated. In vitro analyses of mouse and human 1a and 
1c promoters demonstrated that both depend on Sp1 [23-26], which is known to be also 
involved in insulin-dependent gene regulation [27]. Insulin-dependent control of mouse 
and human SREBP1c promoter activity further involves auto-regulation by SREBP1 protein 
[19, 26], which has not been described for the 1a promoter. We here showed that SREBP1a 
is also susceptible to the inhibition of site 1 protease, suggesting possible auto-regulation 
by SREBP protein, however much weaker than 1c and to an interindividual variable extent. 
Thus, both co-regulation and regulation of one by the other may contribute to the correlation 
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A minor role of SREBP1a in hepatic SREBP-target gene expression had been suggested by 
the fact that 1a-deficient mice did not show any compromised expression of lipid metabolism 
genes, with the single exception of a reduced expression of Acacb [28]. In contrast, we here 
clearly showed by SREBP1a-specific knock-down using exon 1a-specific siRNA that this 
isoform impacts on the expression of further lipogenic SREBP-target genes in human liver 
cells. Apart from ACACB, mRNA expression of ACSS2, ACACA, FASN, SCD, THRSP and INSIG1 
were also affected by specific knock-down of SREBP1a. 
With the exception of ACACB, knock-down of 1a reduced the expression of most SREBP-
target genes to a smaller extent than treatment with PF-429242. This difference may be 
explained by the fact that inhibition of site 1 protease not only impairs the function of SREBP1 
but also of SREBP2 and of further transcription factors, which reside as transmembrane 
precursor proteins in the endoplasmic reticulum, as e.g. ATF6 [29] and the liver-specific 
CREBH [30]. While ATF6 was shown to exert inhibitory effects on hepatic lipogenesis 
[31], murine CREBH was shown to participate in the transcriptional activation of lipogenic 
enzyme genes, as e.g. Fasn, Acaca, Scd and Elovl6 [32]. In mice, a partial overlap of SREBP1 
and -2 in the regulation of lipogenic SREBP-target genes was elegantly demonstrated by a 
combinatorial whole genome transcriptomic analysis in SREBP1- and SREBP2-transgenics 
as well as SCAP knock-out mice [33]. Except for Acacb, Scd and Thrsp, murine orthologues 
of all the other lipogenic enzyme genes, which have been analyzed in this study, proved to be 
regulated by both SREBP1 and SREBP2, even if half of them demonstrated a clear preference 
for SREBP1 [33]. Furthermore, siRNA-mediated knock-down of SREBP1 showed an efficacy 
of about 80%, thereby leaving residual 20% of expression. Even if the effect of siRNA may 
be regarded as being more specific compared to pharmacological inhibition, it is not as 
complete as the latter. 
Strikingly, expression of ACLY and ELOVL6 was not affected significantly by SREBP1 
knock-down at all. In mice, ACLY was shown to be nearly equally well regulated by SREBP1 
and -2 [33], thus the latter may compensate here most efficiently for the loss of SREBP1. 
In contrast to ACLY, expression of which was not reduced by SREBP1 knock-down in any 
hepatocyte culture, ELOVL6 was clearly affected in one of them. This demonstrates that 
interindividual variability of effects combined with the small number of cultures, which have 
been used, represents a limitation of our analysis. 
Surprisingly, simultaneous knock-down of both isoforms was not more efficient in 
reducing the expression of most SREBP-target genes than knock-down of 1a alone, even if 
the latter resulted only in about 60% knock-down of total mature SREBP1 protein, whereas 
the former achieved respective knock-down efficiency of 90% (see Fig. 5C). In mice, knock-
out of SREBP1 resulted in compensatory up-regulation of SREBP2 [34, 35], which also may 
have happened in the case of SREBP1 knock-down by pan-SREBP1 siRNA, as this reduced 
total SREBP1 protein levels much stronger than 1a-specific knock-down. Alternatively, these 
results may indicate that SREBP1c does not contribute significantly to the regulation of these 
genes in cultured primary human hepatocytes, as it represents the weaker transcriptional 
activator of both isoforms and is not expressed in such a large surplus compared to 1a as in 
mice. Only THRSP and INSIG1 were reduced more strongly by knock-down of both isoforms 
than by 1a-specific knock-down, suggesting that SREBP1c may exert a specific function in 
their regulation. Further studies using SREBP1c-specific siRNA are required to prove these 
hypotheses. In conclusion, these data clearly indicate that human SREBP1a has a much 
broader and, most likely due to its higher expression, stronger effect on hepatic lipogenic 
gene expression than its mouse orthologue. 
It is already known from many studies, that SREBP1 is up-regulated in NAFLD, which 
is usually attributed to an increase in SREBP1c. However, following a thorough literature 
analysis, we determined that most of these studies had measured total SREBP1, without 
discriminating between the isoforms. Only two studies specifically quantified SREBP1c [36, 
37], and two others specifically measured SREBP1a, apparently without noticing [38, 39], 
thereby confirming our results [16, and this study]. Given the here shown participation 
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be hypothesized that the 1a isoform contributes to distinct pathogenic pathways in the 
development of NAFLD. Besides regulating the expression of genes promoting de novo 
lipogenesis, as e.g. ACACA, FASN, SCD and THRSP, which were previously shown to be up-
regulated in NAFLD progression [16, 40], SREBP1a was here shown to further regulate 
human ACACB. This gene encodes acetyl-CoA carboxylase (ACC) 2, which participates in the 
negative control of mitochondrial fatty acid β-oxidation [41]. In parallel to SREBP1a, ACACB 
mRNA also increased with NAFLD progression (data not shown). If this further translates 
into elevated ACC2 protein and activity levels, fatty acid β-oxidation should be reduced, 
which may contribute to hepatic steatosis. 
In conclusion, we have clearly shown here that human SREBP1a contributes 
considerably stronger to the total hepatic SREBP1 pool and has a much stronger impact 
on hepatic lipogenic gene expression, both quantitatively and qualitatively, than mouse 
SREBP1a. Given the crucial role of lipogenesis in NAFLD etiology and progression, our data 
support a pathophysiological role of SREBP1a in human hepatic lipogenesis and emphasize 
importance of its interindividual expression variability.
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